171 related articles for article (PubMed ID: 15015891)
1. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
Dimopoulos MA; Anagnostopoulos A
Semin Hematol; 2003 Oct; 40(4 Suppl 4):8-16. PubMed ID: 15015891
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Barlogie B
Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Rajkumar SV
Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K
Semin Hematol; 2003 Oct; 40(4 Suppl 4):3-7. PubMed ID: 15015890
[TBL] [Abstract][Full Text] [Related]
5. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide and dexamethasone combination for refractory multiple myeloma.
Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N
Ann Oncol; 2001 Jul; 12(7):991-5. PubMed ID: 11521808
[TBL] [Abstract][Full Text] [Related]
7. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
8. The role of immunomodulatory drugs in multiple myeloma.
Anderson KC
Semin Hematol; 2003 Oct; 40(4 Suppl 4):23-32. PubMed ID: 15015893
[TBL] [Abstract][Full Text] [Related]
9. Low dose thalidomide in patients with relapsed or refractory multiple myeloma.
Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H
Leuk Lymphoma; 2003 Nov; 44(11):1943-6. PubMed ID: 14738147
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.
Kwon J; Min CK; Kim K; Han JJ; Moon JH; Kang HJ; Eom HS; Kim MK; Kim HJ; Yoon DH; Lee JO; Lee WS; Lee JH; Lee JJ; Choi YS; Kim SH; Yoon SS
Cancer Med; 2017 Jan; 6(1):100-108. PubMed ID: 27905203
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in multiple myeloma: past, present and future.
Harousseau JL
Future Oncol; 2006 Oct; 2(5):577-89. PubMed ID: 17026450
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
13. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide treatment in multiple myeloma.
Strasser K; Ludwig H
Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
17. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G
Clin Lymphoma; 2003 Jun; 4(1):32-5. PubMed ID: 12837152
[TBL] [Abstract][Full Text] [Related]
19. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
García-Sanz R; González-Fraile MI; Sierra M; López C; González M; San Miguel JF
Hematol J; 2002; 3(1):43-8. PubMed ID: 11960395
[TBL] [Abstract][Full Text] [Related]
20. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
Prince HM; Schenkel B; Mileshkin L
Leuk Lymphoma; 2007 Jan; 48(1):46-55. PubMed ID: 17325847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
